DOCSLIB.ORG

Drugs Schedule of Rate Contract

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Employees' State Insurance Corporation MEDICAL RATE CONTRACT DRUGS SCHEDULE OF RATE CONTRACT ENQUIRY NO: U-25/12/138/2012-Med.V Item No. Item Name description of items Packing I DRUGS FOR GASTRO INTESTINAL SYSTEM A ANTACID 560 Antacid Tab. Each tab. to contain: Dried Aluminium Hydroxide gel 240mg, 10 tabs. Mag. Hydroxide 100mg, Mag. Carbonate 60mg, Activated Dimethicone 25mg. 1001 Antacid Tab. Each tab. to Contain: Mag. Hydroxide 400 mg, Dried 10 tabs. Aluminium Hydroxide Gel 400 mg, Activated Dimethicone 125 mg. 1003 Antacid Gel Each 5 ml. to contain: Dried Alumunium Hydroxide gel 400mg, 210ml. Bot Magnesium Trisilicate 400 mg,Simethicone 25 mg, Magnesium Hydroxide 150 mg. 1004 Antacid Gel Each 5 ml. to contain: Magnesium Hydroxide 100 mg (added 170ml. Bot as mag. Hydroxide paste), Aluminium Hydroxide Gel 5 gm, Activated Dimethicone 125 mg,Sorbitol Solution 645 mg. 1344 Antacid gel Each 5ml. to contain: Aluminium Hydroxide 6g, Mag. 180ml. Bot. Hydroxide 80mg., Activated Dimethicone 100mg., Deglycycrrhizinated Liquorice eqv. to Liquorice 400mg. 1495 Antacid Gel Each 5ml contains: Dried Aluminium Hydroxide Gel 300mg, 170ml Bottle Magnesium Hydroxide 250mg, Activated Simethicone 40mg 1740 Antacid Gel Each 10ml to contain: Sucralfate 1000mg,Oxetacaine 20mg. 100ml Bot. B H2 BLOCKERS AND ULCER HEALING DRUGS 567b Rabeprazole Tab. Each tab. to contain: Rabeprazole 20 mg. 10 tabs. 1496 Rabeprazole sodium+ Cap. Rabeprazole sodium 20mg Mosapride Citrate 15mg 10 cap. sustained release Mosapride Citrate Cap. 1497a Esomeprazole Tab./cap. Each tab./cap. To contain: Esomeprazole Magnesium 20 mg 10 Cap/Tab 1497b Esomeprazole Tab/cap Each Tab/cap to contain: Esomeprazole Magnesium 40 mg. 10 Cap/Tab 1741 Troxipide Tab. Each tab. to contain: Troxipide 100mg. 10Tabs. C LAXATIVES 415 Laxative Liquid Each. 5 ml. to contain: Liquid Parafin1.25ml., Milk of 110ml. Bot. Magnesia 3.75ml., Sodium Picosulphate 3.33mg. 478 Lactulose Syp. Each 15 ml. to contain Lactulose 10gm. 100ml. Bot. E ANTI EMETICS 14 Promethazine Inj. Each ml. to contain: Promethazine 25mg. 2ml. amp. 387 Ondansetron Tab. Each tab. to contain: Ondansetron 4mg. 10 tabs. 1014 Domperidone Susp. Each ml . to contain : Domperidone 1 mg. 30 ml. bot 1015a Prochlorperazine tab. Each tab. to contain : Prochlorperazine Maleate 5 mg. 10 tabs. 1016 Prochlorperazine Inj. Each ml. to contain : Prochlorperazine 12.5 mg. 1ml. Amp 1498 Meclizine hcl+Nicotinic Each Tab.to contain: Meclizine HCL 12.5 mg, Nicotinic Acid 10 Tab. 50 mg. Acid Tab. Page 1 of 25 Item No. Item Name description of items Packing 1657 Palonosetron Each 1.5 ML Contains: Palonosetron Hydrochloride equivalent 1.5 ML to Palonosetron 0.075 mg water for Inj.q.s. Hydrochloride Inj. F ANTI-SPASMODIC/DRUGS MODIFYING INTESTINAL MOTILITY 16 Antispasmodic Each ml. to contain: Dicyclomine Hcl 10 mg. Activated 10 ml. Bot. Dimethicone 40mg. Drops/suspension 19 Dicyclomine Inj. Each 2ml. to contain: Dicyclomine 10 mg. 2ml. amp. 517 Dicyclomine + Each 2ml. to contain: Dicyclomine 20mg., Diclofenac sodium 2 ml amp. 50mg. Diclofenac Inj. 1019 Drotaverine Tab. Each Tab. To contain:Drotavarine Hcl 80 mg. 10 tabs. 1346 Dicyclomine + Each tab. to contain: Dicyclomine 10mg., Mefenamic Acid 10 tabs. 250mg. Mefenamic Tab. 1499 Otilonium Bromide Tab. Each Tab.to contain: Otilonium Bromide 40 mg 10 tab. G ANTI-DIARRHOEAL 1501 Ofloxacin +Ornidazole Each Tab.to contain:. Ofloxacin 200mg, Ornidazole 500mg. 10 Tab Tab. 1502 Ofloxacin + Ornidazole Each 100ml to contain:Ofloxacin 200mg , Ornidazole 700mg 100ml Bottle Inj. 1658 Syrup Zinc Each 5ml to contain: Elemental Zinc 20mg 100ml 1742 Pre & Probiotic and Each Pack-in-Pack Sachet WHO ORS Pack 4.10g contains: Sachet Sodium Chloride 0.52g, Sodium Citrate 0.58g,Potassium Oral Rehydration Chloride 0.3g,Dextrose Anhydrous 2.7g. Pre & Probiotic Pack 0.5g contains: Streptococcus Faecalis T- 110 7.5 Million,Clostridium Butyricum TO-A 0.5 Million,Bacillus Mesentericus TO-A 0.25 Million,Lactobacillus Sporogenes 20.0 Million. H FOR LIVER DISORDERS 1504 Liver Disorders Syp. Each 10ml contain: Tricholine Citrate 0.55gm, Sorbitol 7.15gm. 200 ml 1659 Liver Disorders Inj. Each 5 ml to contains : Essential phospholipids 250mg Benzyl 5ml Amp./Vial alcohol 45mg (Preservative) Water for Injection Q.S. 1743 Ademetionine Tab. Each tab. to contain: Ademetionine 400mg 10Tabs. I DIGESTIVE ENZYME 534 Pre & Probiotic Cap. Each cap. to contain: Streptococcus faecalis 30 million, 10 caps. Clostridium butyricum 2 million, Bacillus mesentericus 1 million, Lactic acid bacillus sporogenes 50 mlllion. 1414 Prebiotic and Probiotic Each Sachet (0.5gm) contains: Streptococcus faecalis T-110 Sachet 30million Clostridium butyricum To-A 2million bacillus mesentericus To A 1 Million Lactic Acid bacillus 50 million (Lactobacillus sporogenes) 1506 Bacillus clausii spores Each 5ml to contain: Bacillus clausii spores 2 Billion spores, 5 ml susp.in 5ml distilled water susp. 1507 Pre & Probiotic Each cap.to contain: Streptocoocus Faecalis T - 110 60 10 Caps. Million, Closlridium Butyricum TO-A 4 Million Bacillus Mesentericus TO-A 2 Million, Lactic Acid Bacillus 100 Million. (Lactobacillus Sporogenes) Page 2 of 25 Item No. Item Name description of items Packing J DRUGS ACTING ON COLON AND RECTUM 358 Haemorrhoidal cream Containing: Beclomethasone dipropionate 0.025 %, 20 gm tube Phenylepherine Hydrochloride 0.1 %, Lignocaine hydrochloride 2.5 %. 381 Mesalazine Tab. Each tab to contain: Mesalazine (5-Aminosalicylicacid) 400mg. 10 tabs. 1031 Haemorroidal Oint. Each gm. to contain : Framycetin sulphate 10 mg. 10 gm. tube Hydrocortisone Acetate 5.5 mg. Heparin 100 IU Esculoside 10 mg. Ethyl Amino Benzoate 10 mg,Butyl amino benzoate 10 mg. 1510 Suppository Glycerin Each suppository to contain: Glycerin 2mg Suppository 1511 Euphorbia Prostata Tab. Each tab.to contain: Euphorbia Prostata dry extract ethanolic 7 tabs. 80% (v/v) 100mg 1756 Haemorroidal oint. Containing: Lignocaine Hydrochloride 2% w/w,Hamamelis 20 gm tube water 5%,Zinc Oxide 10% w/w.ointment base q.s. II DRUGS FOR RESPIRATORY SYSTEM A BRONCHODILATORS 582 Ambroxyl + Salbutamol Each tab. to contain: Ambroxol 30mg., Salbutamol 2mg., 10 tabs. Theophylline (anhydrous) 100mg. + Theophylline tab. 1032 Etophylline & Each tab. to contain : Etophylline 77 mg.,Theophylline 23 mg. 10 tabs. Theophylline Tab. 1034b Terbutaline Tab. Each tab. to contain: Terbutaline sulphate 5 mg 10 tabs. 1036 Terbutaline Injection Each ml. to contain :Terbutaline sulphate 0.5 mg. 1ml. Amp. 1512 Ambroxol Hcl +N - Each Tab.to contain: Ambroxol Hydrochloride 30 mg, N - 10 tab. Acetyl - L - Cysteine 200 mg, Acetyl -L-Cysteine Tab 1513 Montelukast + Each Tab.to contain: Montelukast 10mg, Levocetrizine 5mg. 10 tab. Levocetrizine Tab. 1514a Bractant Inj. Each ml to contain: Bractant (as phospholipid) 25mg, 4ml 1514b Bractant Inj. Each ml to contain: Bractant (as phospholipid) 25mg, 8ml 1662 Ebastine + Montelukast Each Tab. to contains: Ebastine 10mg, Montelukast 10mg 10 Tabs. Tab. 1744 Acebrophylline Cap. Each cap. to contain: Acebrophylline 100mg 10 Caps. 1745 Doxofylline Tab. Each tab. to contain: Doxofylline 400mg 10Tabs. 1746 Omalizumab Inj. Each vial to contain: Omalizumab 150mg, Vial B COUGH LINCTUS/EXPECT/BRONCHODILATOR SYRUP 31 Salbutamol Syp. Each 5 ml to contain: Salbutamol sulphate eqv. to Salbutamol 100ml bot. 2 mg 516 Etophylline & Each 5 ml. to contain: Etophylline 46.5mg. , Theophylline 100ml. Bot. 14mg. Theophylline Syp. 1046 Bronchodilator Syp. Each 10 ml.to contain: Bromhexine Hcl 8 mg. Terbutaline 100 ml. bot. Sulphates 4 mg., Guaphanesin 200 mg. 301 Cough Linctus Each 5 ml to contain : Codeine phosphate 10mg, 100ml. Bot. Chlorpheniramine maleate 4 mg. 1343 Cough Syp. Each 5 ml to contain : Methdilazine 2.5 mg , Amm. Chloride 115 ml bot. 100 mg, sodium citrate 50 mg. 1515 Cough Syp. Each 5ml to contain: Dextromethorphan Hydrobromide 7.5 100ml bot. mg, Cetrizine 2.5 mg,Zinc gluconate eq. to elimental Zinc 7.5mg, Menthol 1.5mg Page 3 of 25 Item No. Item Name description of items Packing 1516 Cough Syp. Each 5 ml to contains: Dextromethorphan Hydrobromide 50ml bot. 10mg.Phenylephrine Hydrochloride 5 mg, Chlorpheniramine Maleate 4mg, Guaiphenesin 100mg. 1517 Cough Syp. Each 5ml to contain:Terbutaline Sulp. 1.25mg, Ambroxol Hyd. 100ml bot. 15mg,Guaiphensesin 50mg, Menthol 1mg 1747 Acebrophylline Syp. Each 5ml to contain : Acebrophylline 50mg 100ml Bot. 1748 Cough Syp. Each 5ml to contains: Cetirizine Hydrochloride 60ml Bot. 5mg,Phenylephrine Hydrochloride 5mg,Dextromethorphan Hydrobromide 10mg, Menthol 1.5mg. C INHALERS 362 Budesonide inhaler Each metered dose to contain : Budesonide 100 mcg. 200 doses. 420a Fluticasone + Each metered dose to contain: Salmeterol 25mcg., 120 doses Fluticasone 50mcg. Salmeterol Inhaler 1039 Salbutamol Inhaler Each metered dose to contain :Salbutamol 100 mcg. 200 doses. 1040b Beclomethasone Inhaler Each metered dose to contain: Beclomethasone dipropionate 200 doses 100mcg. 1041 Salbutamol + Each metered dose to contain: Salbutamol .100 mcg., 200 doses Beclmethasone dipropionate 50 mcg. Beclmethasone Inhaler 1519 Inhaler. Each contain: Budesonide 160 mcg,formoterol fumarate 60 doses. dihydrate 4.5 mcg, lactose monohydrate 730 mcg. 1520 Inhaler Containing: Moulded plastic device containing a foil strip 30/60 doses with30/ 60 regularly placed blisters each containing 50 mcg of salmeterol xinafoate and 250 mcg of Fluticasone propionate 1521 Inhaler Each metered dose to contain: Tiotropium Bromide 120 doses Monohydrate Equ. To Tiotropium 9mcg 1522 Inhaler Each metered dose to contain: Ipratropium
Recommended publications
  • CTRI Trial Data

    CTRI Trial Data

    PDF of Trial CTRI Website URL - http://ctri.nic.in Clinical Trial Details (PDF Generation Date :- Wed, 29 Sep 2021 01:52:07 GMT) CTRI Number CTRI/2013/09/003944 [Registered on: 02/09/2013] - Trial Registered Retrospectively Last Modified On 26/07/2013 Post Graduate Thesis Yes Type of Trial Interventional Type of Study Drug Study Design Randomized, Parallel Group, Multiple Arm Trial Public Title of Study A comparative study to evaluate the efficacy and safety of Troxipide (100 mg) and Rabeprazole (20 mg) alone and in combination in patients of Acid peptic disorders. Scientific Title of A prospective, comparative, controlled, randomized, open label, parallel, 3-arm study to evaluate Study and compare the efficacy and safety of Troxipide (100 mg) and Rabeprazole (20 mg) alone and in combination in patients suffering from acid peptic disorders Secondary IDs if Any Secondary ID Identifier NIL NIL Details of Principal Details of Principal Investigator Investigator or overall Name Dr Sagar Katare Trial Coordinator (multi-center study) Designation Junior Resident Affiliation Government Medical College, Aurangabad Address Department of Pharmacology, 3rd floor, College building, Government Medical College and Hospital (GHATI), Panchakki road, Navkheda Aurangabad MAHARASHTRA 431001 India Phone 9029015821 Fax Email [email protected] Details Contact Details Contact Person (Scientific Query) Person (Scientific Name Dr Kantilal Chandaliya Query) Designation Associate Professor Affiliation Government Medical College, Aurangabad Address Department of Pharmacology,
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Jp Xvii the Japanese Pharmacopoeia

    Jp Xvii the Japanese Pharmacopoeia

    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
  • Multi-Layered Pharmaceutical Composition for Both Intraoral and Oral Administration

    Multi-Layered Pharmaceutical Composition for Both Intraoral and Oral Administration

    Europäisches Patentamt *EP001260216A1* (19) European Patent Office Office européen des brevets (11) EP 1 260 216 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: A61K 9/24, A61K 9/00, 27.11.2002 Bulletin 2002/48 A61K 9/48 (21) Application number: 02007778.0 (22) Date of filing: 06.04.2002 (84) Designated Contracting States: • Midha, Kamal K. AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Hamilton HM 12, Bermuda (US) MC NL PT SE TR • Hirsh, Mark Designated Extension States: Wellesley, MA 2481 (US) AL LT LV MK RO SI • Lo, Whe-Yong Canton, MA 02021 (US) (30) Priority: 15.05.2001 US 858016 (74) Representative: (71) Applicant: Peirce Management, LLC COHAUSZ DAWIDOWICZ HANNIG & PARTNER Wellesley, MA 02481 (US) Schumannstrasse 97-99 40237 Düsseldorf (DE) (72) Inventors: • Hirsh, Jane C. Wellesley, MA 02481 (US) (54) Multi-layered pharmaceutical composition for both intraoral and oral administration (57) New pharmaceutical composition in unit dos- capable of intraoral administration; and age form 1 are disclosed for both intraoral and oral ad- ministration to a mammalian patient, said unit dosage (b) as a second portion 4 located within said first form configured to be placed intraorally of said patient, portion 3, a therapeutically effective amount of at which comprises: least one pharmaceutically active ingredient capa- ble of oral administration and which is releasable (a) as a first portion 3 , at least one discrete outer and orally ingestible by the patient after the outer layer comprising a therapeutically effective amount layer has disintegrated or has dissolved intraorally.
  • Aplace® Aplace®

    Aplace® Aplace®

    Kyorin Pharmaceutical Co., Ltd. 1 Revised: March 2010 (9th version) Standard Commodity Classification No. of Japan 872329 - Agent for gastritis and gastric ulcer- ® APLACE Tablets 100 mg < The Japanese Pharmacopoeia Troxipide tablets > ® APLACE Fine Granules 20% < The Japanese Pharmacopoeia Troxipide fine granules > Storage Tablets 100mg Fine Granules 20% Store at room temperature. Approval No. 16100AMZ03249000 22000AMX00662000 Date of listing in the NHI June 1986 June 2008 reimbursement price Expiration date Date of initial marketing in Japan July 1986 February 1989 This product should be used before Date of latest reexamination September 1993 the expiration date specified on the Date of latest approval of indications September 1991 package. International birth date July 1986 DESCRIPTION Taste Slightly sweet at Product description - first, then tasteless APLACE APLACE Fine or slightly bitter Tablets 100 mg Granules 20% Odor - Faint odor Active ingredient JP Troxipide 100 JP Troxipide 200 mg (in one mg (in 1g) INDICATIONS tablet) Gastric ulcers Inactive ingredient Corn starch, less Less substituted Amelioration of gastric mucosal lesions (erosion, hemorrhage, substituted hydroxypropyl- redness and edema) in the following diseases: acute gastritis, hydroxypropyl- cellulose, sodium acute exacerbation stage of chronic gastritis. cellulose, alginate, calcium magnesium lactate hydrates, DOSAGE AND ADMINISTRATION stearate, corn starch, The usual adult dosage for oral use is 100 mg of troxipide (one hypromellose, aspartame (L- tablet or 0.5 g of fine granules) three times daily after meals. carnauba wax phenylalanyl The dosage may be adjusted depending on the patient's age and compound), flavor symptoms. Type of tablet Film-coated Fine granules tablet PRECAUTIONS Color White Faint to pale 1.
  • (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel Et Al

    (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel Et Al

    USOO698.6901B2 (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel et al. (45) Date of Patent: Jan. 17, 2006 (54) GASTROINTESTINAL COMPOSITIONS 6,121,301 A 9/2000 Nagasawa et al. 6,127,418 A 10/2000 Bueno et al. (75) Inventors: Gerard M. Meisel, Budd Lake, NJ 6,156,771. A 12/2000 Rubin et al. S. Arthur A. Ciociola, Far Hills, NJ FOREIGN PATENT DOCUMENTS CA 967977 5/1975 (73) Assignee: Warner-Lambert Company LLC, CA 2136164 3/1995 Morris Plains, NJ (US) CN 1092314 3/1993 CN 1118267 5/1994 (*) Notice: Subject to any disclaimer, the term of this DE 9859.499 : 12/1998 patent is extended or adjusted under 35 E. O S. A1 3.10: U.S.C. 154(b) by 234 days. FR 2244469 8/1973 FR 4506 8/1993 (21) Appl. No.: 10/196,053 FR 277 1009 11/1997 JP 56128719 3/1980 (22) Filed: Jul. 15, 2002 JP 306.6627 8/1989 O O JP 9052829 6/1995 (65) Prior Publication Data WO WO 95.01803 A1 * 1/1995 US 2004/0013741 A1 Jan. 22, 2004 WO WO 9725,979 1/1996 WO WOOO765OO 12/2000 (51) Int. Cl. WO WOO121601 3/2001 A6IF I3/00 (2006.01) ZA 61O1840 8/1993 A6F 99.6A06 3032006.O1 OTHER PUBLICATIONS A6 IK 948 (2006.01) JW Read, JL Abitbol, KD Bardhan, PJ Whorwell, B Fraitag-"Efficacy and Safety of the peripheral kappa ago (52) U.S. Cl. ....................... 424/436; 424/422; 424/430; nist fedotoZine verSuS placebo in the treatment of functional 424/433; 424/451; 424/464; 424/489 dyspepsia see comments)." Gut Nov., 1997 41(5):664-8.
  • Estimation of Troxipide in Tablet Dosage Form by Rp-Hplc

    Estimation of Troxipide in Tablet Dosage Form by Rp-Hplc

    International Journal of Pharmacy and Pharmaceutical Sciences Academic Sciences ISSN- 0975-1491 Vol 3, Suppl 4, 2011 Research Article ESTIMATION OF TROXIPIDE IN TABLET DOSAGE FORM BY RP-HPLC RAVI PRATAP PULLA*, Dr.B.S.SASTRY#, Dr.Y.RAJENDRA PRASAD¶, Dr.N.APPALA RAJU *Department of Pharmaceutical Chemistry, SSJ College of Pharmacy, V.N.Pally, Gandipet, Hyderabad, #Department of Pharmaceutical Chemistry, Principal & Professor, Medak Institute of Technology-Pharmacy, Kothapet (V), Near Narsapur, Shivampet, Medak District, ¶Department of Pharmaceutical Chemistry, Professor, Andhra University – College of Pharmaceutical Sciences, Peda Waltair, Visakhapatnam, Department of Pharmaceutical Chemistry, Associate Professor, Sultan-Ul-Uloom College of Pharmacy, Mount Pleasant, Banjara Hills, Hyderabad. Email: [email protected] Received: 4 June 2011, Revised and Accepted: 13 July 2011 ABSTRACT A simple, precise, rapid and accurate Reverse Phase HPLC method was developed for the estimation of Troxipide in tablet dosage form. An Inertsil ODS-3V, 250x4.6 mm, column with 5 µm particle size and the mobile phase consisting of 0.03M Ammonium Acetate in water pH: 3.2 adjusted with Acetonitrile (50:50). Acetonitrile in the isocratic mode was used. The flow rate was 0.8 ml/min and the effluents were monitored at 212 nm. The retention time was 3.046 min. The detector response was linear in the concentration of 10-120 mcg/mL for Troxipide. The respective linear regression equation being Y (-105593.8824) = 65647.112x + 45974.1647 for Troxipide. The Limit of Detection (LOD) and The Limit of Quantification (LOQ) were 1 mcg/mL and 3 mcg/mL respectively for Troxipide. The percentage assay of Troxipide was 98.17 %.
  • Clinical Study Troxipide in the Management of Gastritis: a Randomized Comparative Trial in General Practice

    Clinical Study Troxipide in the Management of Gastritis: a Randomized Comparative Trial in General Practice

    Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2010, Article ID 758397, 7 pages doi:10.1155/2010/758397 Clinical Study Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice Bhupesh Dewan and Aarthi Balasubramanian Medical Services Department, Zuventus Healthcare Ltd, 5119, ‘D’ Wing, Oberoi Garden Estates, Chandivali, Mumbai 400072, India Correspondence should be addressed to Bhupesh Dewan, [email protected] Received 2 August 2010; Revised 29 September 2010; Accepted 13 October 2010 Academic Editor: R. Fass Copyright © 2010 B. Dewan and A. Balasubramanian. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. A trial of empirical acid-suppressive therapy is the usual practice for most patients with symptoms of gastritis in primary care. Aim. To assess the relative efficacy of Troxipide and Ranitidine in patients with endoscopic gastritis over a four-week period. Methods. In all, 142 patients were randomized to Troxipide (100 mg tid) or Ranitidine (150 mg bid) for a period of four weeks. The severity of the signs of endoscopic gastritis at baseline and week 4 using a four-point scale and the subjective symptom severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results. Troxipide was found to be superior to Ranitidine for both, the complete resolution and improvement of endoscopic gastritis. Higher proportion of patients showed complete healing of erosions (88.14%), oozing (96.77%), and edema (93.88%) with Troxipide as compared to Ranitidine (P<.01).
  • Clinical Study Troxipide in the Management of Gastritis: a Randomized Comparative Trial in General Practice

    Clinical Study Troxipide in the Management of Gastritis: a Randomized Comparative Trial in General Practice

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2010, Article ID 758397, 7 pages doi:10.1155/2010/758397 Clinical Study Troxipide in the Management of Gastritis: A Randomized Comparative Trial in General Practice Bhupesh Dewan and Aarthi Balasubramanian Medical Services Department, Zuventus Healthcare Ltd, 5119, ‘D’ Wing, Oberoi Garden Estates, Chandivali, Mumbai 400072, India Correspondence should be addressed to Bhupesh Dewan, [email protected] Received 2 August 2010; Revised 29 September 2010; Accepted 13 October 2010 Academic Editor: R. Fass Copyright © 2010 B. Dewan and A. Balasubramanian. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. A trial of empirical acid-suppressive therapy is the usual practice for most patients with symptoms of gastritis in primary care. Aim. To assess the relative efficacy of Troxipide and Ranitidine in patients with endoscopic gastritis over a four-week period. Methods. In all, 142 patients were randomized to Troxipide (100 mg tid) or Ranitidine (150 mg bid) for a period of four weeks. The severity of the signs of endoscopic gastritis at baseline and week 4 using a four-point scale and the subjective symptom severity at baseline and week 2 & week 4 using a Visual analog scale (VAS) were documented. Results. Troxipide was found to be superior to Ranitidine for both, the complete resolution and improvement of endoscopic gastritis. Higher proportion of patients showed complete healing of erosions (88.14%), oozing (96.77%), and edema (93.88%) with Troxipide as compared to Ranitidine (P<.01).
  • Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm

    Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm

    Known Bioactive Library: Selleck Bioactive 10mM, 3.33mM, 1.11mM ICCB-L Plate (10mM / 3.33mM / ICCB-L Max Solubility Vendor ID Compound Name Pathway Targets Information CAS Number Form URL 1.11mM) Well in DMSO (mM) Afatinib (BIBW2992) irreversibly inhibits EGFR/HER2 including EGFR(wt), http://www.selleckchem.c Protein Tyrosine EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 3651 / 3658 / 3665 A03 S1011 Afatinib (BIBW2992) 199 EGFR,HER2 439081-18-2 free base om/products/BIBW2992. Kinase nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib- html resistant L858R-T790M EGFR mutant. Phase 3. http://www.selleckchem.c Deflazacort(Calcort) is a glucocorticoid used as an anti-inflammatory and 3651 / 3658 / 3665 A04 S1888 Deflazacort 199 Others Others 14484-47-0 free base om/products/Deflazacor. immunosuppressant. html http://www.selleckchem.c Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with 3651 / 3658 / 3665 A05 S1198 Irinotecan 17 DNA Damage Topoisomerase 97682-44-5 free base om/products/Irinotecan.ht IC50 of 15.8 μM and 5.17 μM, respectively. ml Enalapril Maleate, the active metabolite of enalapril, competes with http://www.selleckchem.c Endocrinology & 3651 / 3658 / 3665 A06 S1941 Enalapril Maleate 201 RAAS angiotensin I for binding at the angiotensin-converting enzyme, blocking the 76095-16-4 maleate om/products/Enalapril- Hormones conversion of angiotensin I to angiotensin II. maleate(Vasotec).html BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC, respectively.